-+ 0.00%
-+ 0.00%
-+ 0.00%

*Karyopharm Therapeutics: Existing Liquidity, Including Cash, Cash Equivalents, Investments, Cash Flow From Net Pdt Rev and License and Other Rev Will Enable Co to Fund Current Operating Plans Into 2Q of 2026 >KPTI

Dow Jones·02/12/2026 12:33:00

Please log in to view news